What is the #NotMyNormal Campaign?
Women experience a multitude of symptoms – indicative of all different diseases – that often go untreated, undocumented and undiagnosed because we don't talk about what is normal. We want to remove the stigma around talking about women's health issues. What is your normal? Share your story on social media, tag us and use #NotMyNormal.
Aspira Women's Health has partnered with Bright Pink to raise awareness for Ovarian Cancer #PowerfulTogether.
Aspira Women's Health is helping to transform women’s health with the discovery, development, and utilization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. Our FDA-cleared products OVA1® and OVERA® detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, Aspira GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of experience in ovarian cancer risk assessment, Aspira Women's Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans.
Bright Pink helps to save lives from breast and ovarian cancer by empowering women to know their risk and manage their health proactively.